Trial Profile
A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 09 Nov 2019 Planned End Date changed from 1 Feb 2020 to 1 Sep 2020.
- 09 Nov 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 19 Apr 2017 New trial record